首页 | 本学科首页   官方微博 | 高级检索  
检索        

不同化疗药物膀胱灌注预防浅表性膀胱癌术后复发的疗效比较
引用本文:林涛,孙立江.不同化疗药物膀胱灌注预防浅表性膀胱癌术后复发的疗效比较[J].中外医疗,2016(34).
作者姓名:林涛  孙立江
作者单位:青岛大学医学院泌尿外科,山东青岛,266000
摘    要:目的:比较吉西他滨与丝裂霉素进行膀胱灌注预防浅表性膀胱癌患者术后复发的效果。方法随机选择2014年10月_2016年5月青岛大学医学院泌尿外科收治的84例浅表性膀胱癌患者,分为观察组和对照组,每组各42例,所有患者均于术后7 d进行膀胱灌注化疗,观察组药物为吉西他滨进行灌注,对照组为丝裂霉素,7 d/次,治疗56 d,此后每月治疗1次,共治疗1年,对比两组患者治疗效果。结果观察组复发率为7.14%显著低于对照组的33.33%,两组对比差异有统计学意义(P<0.05﹚。且观察组和对照组患者不良反应发生率分别为7.14%和38.10%,对比差异具有统计学意义(P<0.05﹚。结论应用吉西他滨进行膀胱灌注对于浅表性膀胱癌术后复发预防效果较好,且不良反应发生率低,具有重要的临床应用价值。

关 键 词:吉西他滨  丝裂霉素  膀胱内灌注  浅表性膀胱癌

Different Intravesical Chemotherapy Drugs Prevention Efficacy of Superfi-cial Bladder Cancer Recurrence Compare
Abstract:Objective To compare gemcitabine and mitomycin chemotherapy for preventing bladder cancer recurrence in patients with superficial bladder effect. Methods Random selection from October 2014 to May 2016 84 cases of superficial bladder cancer patients admitted to Qingdao University Medical College Department of Urology, divided into observation group and control group, each group 42 cases, all patients after surgery 7 days intravesical chemotherapy, observe the group of drugs for the perfusion of gemcitabine, mitomycin control group, once every 7 days, 56 days treatment, after treatment once a month, were treated for 1 year, compared to the treatment groups were . Results Recurrence rate was 7.14% in the observation group was significantly lower than the 33.33% in the control group, a significant difference between two groups (P<0.05). And the observation group and the control group of patients with adverse events was 7.14% and 38.10%, respec-tively, compared to the more significant difference was statistically significant(P<0.05). Conclusion Gemcitabine instillation for superficial bladder cancer recurrence prevention is better, and a low incidence of adverse reactions has important clini-cal value.
Keywords:Gemcitabine  Mitomycin  Intra bladder perfusion  Superficial bladder cancer
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号